Eton Pharmaceuticals, Inc. (ETON)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$50.72-0.45%
Close 2026-11-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
Research Workspace
Put ETON beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 81% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 25% in its worst 12-month stretch.
View RiskETON's strong recent performance has to keep compounding to justify the price. Revenue grew 99% year over year in the latest quarter. The company also beat earnings expectations by 230.8%. It trades at 71 times earnings versus a 13 times peer median. This premium reflects modest expectations versus our view. Management is running behind on a stated commitment. Peer multiples imply a price about 36% below where it trades. Our standing thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. ETON is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering ETON (as of Nov 2026).
Based on 3 Wall Street analysts offering 12-month price targets for ETON in the last 4 months.
Continue this research
Compare ETON with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ETON Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put ETON next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase 2026 revenue to exceed $145 million
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $50.72
The last 12 months of price, then the range of analyst 12-month targets from today’s $50.72.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Forecast aligns with revenue growth objective.
Advances: Deliver at least 35% Adjusted EBITDA margin in 2026
Earnings call supports EBITDA margin target.
Advances: Increase 2026 revenue to exceed $145 million
Record revenue indicates strong growth trajectory.
Advances: Increase 2026 revenue to exceed $120 million
Earnings beat and raised guidance support revenue growth objective.
Advances: Report at least 30% Adjusted EBITDA margin for 2026
Earnings report indicates improved profitability outlook.
Advances: Increase 2026 revenue to exceed $120 million
Analyst support aligns with growth strategy.
Threatens: Report at least 30% Adjusted EBITDA margin for 2026
Mixed results may hinder achieving EBITDA margin.
Threatens: Increase 2026 revenue to exceed $120 million
EPS miss raises concerns about future growth.